ODEFSEY – A NEW TRIPLE COMBO PILL

Posted in Latest News on

ODEFSEY – a new combination pill containing rilpivirine (Edurant - an existing NNRTI), TAF (tenofovir alafenamide), and FTC (Emtriva - emtricitabine) was registered in Australia by Gilead Sciences in October 2016, and has now become available (from 01 May 2017) on the Pharmaceutical Benefits Scheme (PBS) for patient co-payment subsidy.Odefsey is a combination product containing tenofovir alafenamide (TAF) which is... Read more

Updated Cervical Cancer Guidelines for Women – Pap Smear Test to be replaced with HPV test

Posted in Latest News on

01 March, 2017 -The Medical Services Advisory Committee (MSAC) has provided recommendations on new approaches to cervical screening in Australia. Following a comprehensive review of the current evidence for cervical screening, MSAC has recommended for both Human Papilloma Virus (HPV) vaccinated and unvaccinated women that:an HPV test should be undertaken every five years cervical screening should commence at 2... Read more

Could Vaping Help You Quit Smoking?

Posted in Latest News on

QPP in partnership with the University of Queensland are currently completing a small Brisbane-based clinical trial of nicotine containing e-cigarettes as a quit smoking aid. This study is now closed for new participants and we look forward to sharing the results with you later in the year. However, a larger trial is expected to start in 2018 and will be open to PLHIV who smoke and want to quit in QLD, NSW, Victoria and... Read more

Long Acting HIV Treatment: 5 Myths and Realities

Posted in Latest News on

Introduction: Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by?As research progresses on long-acting antiretroviral therapy (LA-ART) for HIV -- also sometimes referred to as extended-release (ER) antiretroviral therapy -- experts disagree about the impact it will have on clinical care. There is both optimism and pessimism regarding LA-ART, and sometimes they come from... Read more

CROI 2017: Bone Density Improves in People Who Switch from Tenofovir DF to Tenofovir Alafenamide

Posted in Latest News on

After 3 years, tenofovir alafenamide (TAF) for first-line HIV treatment was better at suppressing viral load and safer for the bones and kidneys than the older tenofovir disoproxil fumarate (TDF), researchers reported at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in February in Seattle. Another study showed that people with low bone density who switched from TDF to TAF saw improved bone... Read more

A LOOK INTO THE GREY ZONE: AGEING WITH HIV

Posted in Latest News on

Ageing with HIV, can be both a celebration and a concern. A celebration because effective HIV treatments have given life-years back to all people on effective treatment; but a concern since people are now moving into older age with HIV and experiencing age-related health conditions. In Australia, there are approximately 6000-7000 people living with HIV aged over 55 years.  In the US, it has been reported that 50% are... Read more

Give the Flu the Flick

Posted in Latest News on

Yes folks, it’s that time of year again to get flu vaccinated and build up our winter defences against the debilitating effects of influenza. The official flu season typically spans from May to October each year. Flu vaccination is available from March/April.You should get a new flu vaccination every year, because the flu virus is constantly changing and each new vaccine matches the current circulating strains of... Read more

NEW LONG ACTING HIV DRUG CLASS ON THE HORIZON – CAPSID INHIBITORS

Posted in Latest News on

Capsid assembly is the step in the HIV lifecycle where the virus develops a cone-shaped core (capsid) particle, which contains or encloses the viral genetic blueprint (genome), inside a maturing infectious virion. It consists of a protein envelop membrane which protects the viral antigen core genetic proteins (called “p24”). Once released inside the host human cell, the core capsid particle disassembles to allow the... Read more

Bictegravir – A new Integrase Inhibitor in the pipeline

Posted in Latest News on

Bictegravir matches dolutegravir for first-line treatment in Phase 2 studiesPaul Sax at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.comBictegravir, an investigational new integrase inhibitor, was highly potent, well tolerated and worked as well as dolutegravir (Tivicay – an existing integrase inhibitor) in a phase 2 clinical trial of people first starting treatment, according to study results... Read more

Doravirine – a new NNRTI (Non-Nuke) option on the horizon

Posted in Latest News on

Kathleen Squires at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.comDoravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) that reduced HIV viral load as well as boosted darunavir (a Protease Inhibitor) in a phase 3 clinical trial of people starting HIV treatment for the first time; but it had a better lipid (blood fat) profile, according to a late breaking... Read more